Introduction: Safety and tolerability of medications are key variables to inform treatment choice for patients with bipolar disorder (BD). This review focuses on the overall tolerability and safety profile of aripiprazole when used for its bipolar disorder indications, which include acute treatment of manic and mixed episodes and maintenance treatment of bipolar I disorder for the oral formulation, agitation associated with bipolar mania for the injectable immediate-release formulation, and maintenance treatment of bipolar I disorder for the long acting once-monthly (AOM) formulation. Areas covered: The authors reviewed aripiprazole safety in bipolar disorder according to product labeling. English language reports located through PubMed and information available on the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) websites, with a focus on the safety and tolerability of aripiprazole, were reviewed. Expert opinion: Compared to many other antipsychotics, aripiprazole has a relatively favorable tolerability profile, with a lower risk for weight gain, dyslipidemia, diabetes, and hyperprolactinemia. Compared to first-generation antipsychotics, and similar to most second-generation antipsychotics, aripiprazole has a reduced propensity for extrapyramidal side effects and a better cardiovascular safety.

Cuomo, A., Beccarini Crescenzi, B., Goracci, A., Bolognesi, S., Giordano, N., Rossi, R., et al. (2019). Drug safety evaluation of aripiprazole in bipolar disorder. EXPERT OPINION ON DRUG SAFETY, 18(6), 455-463 [10.1080/14740338.2019.1617847].

Drug safety evaluation of aripiprazole in bipolar disorder

Goracci, A.;Bolognesi, S.;Giordano, N.;Fagiolini, A.
2019-01-01

Abstract

Introduction: Safety and tolerability of medications are key variables to inform treatment choice for patients with bipolar disorder (BD). This review focuses on the overall tolerability and safety profile of aripiprazole when used for its bipolar disorder indications, which include acute treatment of manic and mixed episodes and maintenance treatment of bipolar I disorder for the oral formulation, agitation associated with bipolar mania for the injectable immediate-release formulation, and maintenance treatment of bipolar I disorder for the long acting once-monthly (AOM) formulation. Areas covered: The authors reviewed aripiprazole safety in bipolar disorder according to product labeling. English language reports located through PubMed and information available on the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) websites, with a focus on the safety and tolerability of aripiprazole, were reviewed. Expert opinion: Compared to many other antipsychotics, aripiprazole has a relatively favorable tolerability profile, with a lower risk for weight gain, dyslipidemia, diabetes, and hyperprolactinemia. Compared to first-generation antipsychotics, and similar to most second-generation antipsychotics, aripiprazole has a reduced propensity for extrapyramidal side effects and a better cardiovascular safety.
Cuomo, A., Beccarini Crescenzi, B., Goracci, A., Bolognesi, S., Giordano, N., Rossi, R., et al. (2019). Drug safety evaluation of aripiprazole in bipolar disorder. EXPERT OPINION ON DRUG SAFETY, 18(6), 455-463 [10.1080/14740338.2019.1617847].
File in questo prodotto:
File Dimensione Formato  
Drug safety-evaluation of aripiprazole-Cuomo-2019.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 5.55 MB
Formato Adobe PDF
5.55 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Drug safety evaluation Postprint.pdf

accesso aperto

Descrizione: This is an original manuscript of an article published by Taylor & Francis in EXPERT OPINION ON DRUG SAFETY on JUN 3 2019, available at: http://www.tandfonline.com/10.1080/14740338.2019.1617847
Tipologia: Post-print
Licenza: Creative commons
Dimensione 704.62 kB
Formato Adobe PDF
704.62 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1095785